InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,616.84
(
-0.32%
)
US TECH 100
18,992.00
(
-1.08%
)
Dow Jones
41,240.52
(
0.16%
)
Brent Oil
80.29
(
0.02%
)
Bitcoin
63,079.89
(
0.33%
)
Post# of 12660
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

walldiver

Send PM Follow Ignore
Followers 24
Posts 1614
Boards Moderated 0
Alias Born 01/02/2003

walldiver

Re: walk post# 4658

Wednesday, 08/08/2007 7:00:05 PM

Wednesday, August 08, 2007 7:00:05 PM

Post# of 12660
<<...informal inquiry which appears to be related to disclosures regarding the approval process for Provenge and trading in the Company’s stock.>>

One other way this language could be interpreted: it's highly possible (at least a 50-50 chance) that in regards to the "disclosures regarding the approval process" phrase, the SEC is investigating the manner in which DNDN disclosed the CR letter from the FDA, and not investigating the FDA's decision process at all.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up